AIGEA Medical Srl

Verified

Sectors

Artificial Intelligence, Deeptech, Healthcare

Monetization

00 00 00

Audience

00 00 00

Revenue Stage

00 00 00

Product stage

00 00 00

Tags

Digital, Social Impact

Company address

Via Pellizzi 11, Pisa

Company number

IT02431380506

Website

https://www.aigeamedical.com

LinkedIn

00 00 00

Currently Raising
00 00 00
Location
Italy
Committed Capital
00 00 00
Company Description

Breast Cancer is the most frequent type of cancer among women, representing 25% of all the cancers. One woman out of 8 is affected by Breast Cancer along her life. In this context, prevention and early detection of cancer has proven to be crucial: breast screening has therefore become a regular practice, supported by HealthCare systems and covered by protected budgets from SSA (Social Security Administration). Breast screening is performed on the whole range of women population after a certain age, for example in Italy after the age of 45 years. Worldwide 300 million women every year are subject to breast screenings. That’s the reason why we created DeepMammo, a technology based on eXplainable and Generative AI that empowers radiologists in early detection of Breast Cancer. DeepMammo is based on a proprietary technology, which has been registered as a trademark and patented. Exploiting proprietary MultiModal Deep Neural Networks, DeepMammo supports Imaging workflows augmenting radiologists’ performances, improving accuracy, safety, cost-effectiveness and patient journey: it helps mitigate the shortage of radiologists, therefore improving clinical practice in Breast Cancer screenings. Finally, by reducing the cancer screening time and envisaging a personalized screening method, it simplify and speed-up daily screening activities. Doing so, we save women lives.

Read More
Highlights
00 00 00
00 00 00
00 00 00
Management Team
Name Position Description Contact
Federico Picardi Chief Digital Officer & Founder
00 00 00
Paolo Galati CTO
00 00 00
Giulia Benotto AI & NLP Specialist
00 00 00
Tommaso Guidi AI & ML Engineer
00 00 00
Gianfranco Bellezza Clinical Marketing Officer
00 00 00
Carlo Aliprandi CEO & Founder
00 00 00
Key Achievements
  • Nov, 2023
    00 00 00
  • Dec, 2023
    00 00 00
  • Jun, 2024
    00 00 00

Receive premium dealflow

Claim your account now!

Problem
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
Solution
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
Competition
Total Addressable Market
00 00 00
EUR
Serviceable Addressable Market
00 00 00
EUR
Serviceable Obtainable Market
00 00 00
EUR
Company Why we are better
Kheiron Medical
00 00 00
ScreenPoint
00 00 00
Lunit
00 00 00
Financials
# Paying Customers
00 00 00
Revenue (EUR)
00 00 00
CAGR
00 00 00
%
CMGR
00 00 00
%
LTV (EUR)
00 00 00
CAC (EUR)
00 00 00
ARR (EUR)
00 00 00
Monthly burn (EUR)
00 00 00
Runway in months
00 00 00
Gross profit margin
00 00 00
%
Net profit margin
00 00 00
%
Projected Financials

Gain access to full company data by requesting access.

Historical Financials

Gain access to full company data by requesting access.

Current Funding Round
Round Type
00 00 00
Offering Type
00 00 00
Amount to Raise
00 00 00
EUR
Pre-Money Valuation
00 00 00
EUR
Use of Capital
Committed Capital
00 00 00
EUR

Gain access to full company data by requesting access.

Past Funding
Total Past Funding 132,500 EUR
Equity Funding
00 00 00
EUR
Grant Funding
00 00 00
EUR
Debt Funding
00 00 00
EUR
Type Date Amount Round Organizations Valuation Status
Grant 2024-03-01
00 00 00
EUR
00 00 00
00 00 00
00 00 00
00 00 00
Equity 2023-06-01
00 00 00
EUR
00 00 00
00 00 00
00 00 00
00 00 00
Cap Table
Investor Type Issued Shares Stock Options % Issued Shares % Fully Diluted Shares
Federico Picardi
00 00 00
00 00 00
00 00 00
00 00 00
00 00 00
Carlo Aliprandi
00 00 00
00 00 00
00 00 00
00 00 00
00 00 00
Extra Group
00 00 00
00 00 00
00 00 00
00 00 00
00 00 00
Total 0 0 0% 0%